Sacituzumab Govitecan Plus Pembrolizumab Prolongs PFS Among Patients with Previously Untreated, PD-L1-positive, Advanced TNBC By Ogkologos - January 30, 2026 301 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ASCENT-04/KEYNOTE-D19 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Making Cancer Care More Equitable: A Cancer Survivor’s Story July 12, 2023 Breastfeeding Duration Could Influence Breast Cancer Risk, Study Shows September 27, 2019 2023 Highlights in Treating Genitourinary Cancers: Expert Perspectives January 24, 2024 Cancer in My Community: Caring for Children With Cancer in Armenia July 2, 2020 Load more HOT NEWS ESMO Advocates for Equal Access to Optimal Cancer Care for all... Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab Prolongs OS Among... T-DM1 is Active and Well Tolerated in Patients with HER2-positive Metastatic... Shaping Future Oncology Leaders: ESMO Broadens Its Career Development Opportunities
